NCT05835180View on ClinicalTrials.gov

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 18, 2023

Study Completion Date

December 18, 2023

Conditions

Non-alcoholic SteatohepatitisHepatic ImpairmentCirrhosis

Interventions

DRUG

TVB-2640 - 50 mg

TVB-2640 -50 mg administered orally once daily

Trial Locations (3)

32809

Thomas C. Marbury, Orlando

78215

Eric J. Lawitz, MD, San Antonio

H-2143

Geza Lakner, Kistarcsa

All Listed Sponsors

lead

Sagimet Biosciences Inc.

INDUSTRY

NCT05835180 - A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Biotech Hunter | Biotech Hunter